about
Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific regionVX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon CellsManaging Occupational Risks for Hepatitis C Transmission in the Health Care SettingTherapeutic issues in HIV/HCV-coinfected patientsRefractoriness of hepatitis C virus internal ribosome entry site to processing by Dicer in vivoMutations in the E2-PePHD region of hepatitis C virus genotype-3a and correlation with response to interferon and ribavirin combination therapy in Pakistani patientsDisruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation.Antisense oligonucleotide inhibition of hepatitis C virus genotype 4 replication in HepG2 cellsEffects of host and virus related factors on interferon-α+ribavirin and pegylated-interferon+ribavirin treatment outcomes in chronic Hepatitis C patients.Characterization of hepatitis C Virus genotype 3a hypervariable region 1 in patients achieved rapid virological response to alpha interferon and ribavirin combination therapy.Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic options.Intramolecular regulation of the sequence-specific mRNA interferase activity of MazF fused to a MazE fragment with a linker cleavable by specific proteasesNew therapeutic opportunities for hepatitis C based on small RNA.A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patientsThe heat shock protein inhibitor Quercetin attenuates hepatitis C virus production.Divergent antiviral effects of bioflavonoids on the hepatitis C virus life cycle.Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.A cell-permeable hairpin peptide inhibits hepatitis C viral nonstructural protein 5A-mediated translation and virus productionSustained viral response and hematological adverse events during chronic hepatitis C infection treatment.
P2860
Q27026753-AD069F94-BB82-4222-8333-8761BC6A6EE8Q27473228-50604584-CD6F-4945-B8F6-E939B6BC778CQ27477626-F60E7F35-66AE-4E96-99CA-EDE6D82120E7Q27481053-1372C221-2752-4CCD-98BA-D568817B4200Q27489649-00FD1719-0685-47FF-ACC4-ABC1705F17ACQ34481770-859FFF30-4E57-4873-B816-7E9A7002AF30Q34792600-AD52FBFF-264D-4A6F-B379-BE33208BFF82Q34881433-AC57E041-A947-4D1F-B8B0-F7795D0F992DQ35040102-ACBD2584-FCD9-4773-8EFA-CD8CFC5D7F52Q35053127-164F27C6-D41D-4C02-9965-18B561687659Q35824821-4875F330-AD6B-4010-997D-C48B5159E084Q35940944-A98CF352-E20D-4A73-8667-AF416DC1A1C7Q36921336-366505FE-4F96-4AD3-A624-50E7F39F3747Q37105582-338319BA-DB22-42A3-8D5F-99BD7C3A7FC8Q37354782-C04E02F3-0838-4813-90D1-A3C51D330658Q39279264-0F538651-A910-4E18-BB1C-703D2ADB7910Q40344643-CB9C0B77-AC12-4778-AB68-37CA63CA95C2Q42149608-63904BBC-6B0F-4CCE-922E-F4A82D5F4CADQ42554331-79032EB6-1CAB-4F37-B4FA-53F2C27A2861
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Future therapy of hepatitis C.
@ast
Future therapy of hepatitis C.
@en
Future therapy of hepatitis C.
@nl
type
label
Future therapy of hepatitis C.
@ast
Future therapy of hepatitis C.
@en
Future therapy of hepatitis C.
@nl
prefLabel
Future therapy of hepatitis C.
@ast
Future therapy of hepatitis C.
@en
Future therapy of hepatitis C.
@nl
P2860
P356
P1433
P1476
Future therapy of hepatitis C.
@en
P2093
John G McHutchison
Keyur Patel
P2860
P304
P356
10.1053/JHEP.2002.36795
P407
P433
P577
2002-11-01T00:00:00Z